Ferrua, Marie http://orcid.org/0000-0003-3313-6038
Mathivon, Delphine
Duflot-Boukobza, Adeline
Abbas, May
Charles, Cécile
Barrais, Amandine
Legendre, Jennifer
Mendes, Christine
Pons, Magali
Merad, Mansouria
Minvielle, Etienne
Mir, Olivier
Scotté, Florian
Funding for this research was provided by:
Fondation de France
Article History
Received: 11 September 2020
Accepted: 22 December 2020
First Online: 18 January 2021
Compliance with ethical standards
:
: OM has received consultancy fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma. He is a shareholder of Amplitude Surgical, Ipsen, and Transgene. F.S. has a conflict of interests with Mylan, BMS, Tesaro, Sanofi, Roche, MSD, TEVA, Norgine, Prostrakan, Leo Pharma, Janssen, Hospira, Boehringer, Amgen, Pierre Fabre Oncologie, Vifor Pharma, Arrow, and Mundi Pharma. Other authors have no conflict of interest to declare.
: The study was conducted after approval of the Institutional Review Board (CSET), in agreement with applicable laws and regulations, and according to the Helsinki Declaration.
: All patients enrolled in the study completed a written consent form prior to their participation in the study.
: All patients enrolled in the study completed a written consent form for the use and publication of their data.
: Not applicable.
Free to read: This content has been made available to all.